Ming Lu's Archive

info@myelomabeacon.com

 Ming is a current freshman at Princeton University majoring in engineering. Joining Light Knowledge Resources in the fall of 2008, she works on the Myeloma Beacon writing team. When not working on problems sets, Ming enjoys playing Ultimate Frisbee on Lady Clockwork, playing the piano, and watching movies.

Ming Lu has written 9 article(s).

New Clinical Trials Combine Zolinza And Velcade For Multiple Myeloma Treatment
[ by Ming Lu | Jan 19, 2009 11:00 pm | No Comments ]

The Multiple Myeloma Research Consortium (MMRC) announced Friday that it will partner with Merck & Co. to initiate Phase 2B clinical trials of Zolinza (vorinostat) in combination with Velcade (bortezomib). The trial is currently open for the enrollment of patients with relapsed multiple myeloma.

Zolinza, an oral histone deacetylase inhibitor that increases the cellular proteins that prevent cancer, has previously been approved for cutaneous T-cell lymphoma. Velcade has been previously approved…

Read the full story »
Beacon NewsFlashes – January 5, 2009
[ by Ming Lu | Jan 5, 2009 4:55 pm | No Comments ]

The Road To Discovery – The Leukemia & Lymphoma Society (LLS) will hold a workshop on clinical trials on January 8, 2009, from 6 p.m. to 8 p.m. at the Wellness Community in Indianapolis, IN. Guest speaker Dr. Michael Dugan from the St. Francis Indiana Blood and Marrow Transplantation will speak about the basics of clinical trials and how to participate in these new treatments. For more information, visit the LLS Web site.

Walt Disney World Marathon Weekend –…

Read the full story »
Clinical Trials Begin For New Form Of Radiotherapy
[ by Ming Lu | Dec 29, 2008 7:06 pm | No Comments ]

Clinical trials using a new, highly targeted radiotherapy are currently being carried out in the United Kingdom. This new treatment will allow patients to be given a higher dose of radiation to destroy cancer cells in the bone marrow without harming healthy cells. The two-year trial at South General Hospital will involve 80 patients, half who will receive the new radiotherapy with chemotherapy and half with just chemotherapy.

There are several types of radiation treatments commonly used with multiple myeloma.…

Read the full story »
Impact of PET Scans Consistent Across All Types of Cancer
[ by Ming Lu | Dec 13, 2008 11:05 pm | No Comments ]

The National Oncologic PET Registry (NOPR) reported in the Journal of Nuclear Medicine that PET scanning has an impact on the intended treatment of patients with cancer in one third of all cases. The latest results show that PET has a similar impact across all of these cancer types, especially multiple myeloma.

A positron emission tomography (PET) scan is an imaging process that uses a radioactive tracer to depict the organs and tissues in a body. The PET scanner converts…

Read the full story »
Page 1 of 3123»